186 results on '"Rizzo, J. Douglas"'
Search Results
2. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis
3. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
4. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
5. Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes
6. Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report from the BMT CTN Patient and Caregiver Advocacy Task Force
7. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]
8. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]
9. Current Use and Trends in Hematopoietic Cell Transplantation
10. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry
11. Integration of Hematopoietic Cell Transplantation Outcomes Data
12. COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum
13. Screening and prevention guidelines for hematopoietic cell transplant survivors
14. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill
15. Screening and Prevention Guidelines for Hematopoietic Cell Transplant Survivors
16. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
17. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
18. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
19. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome
20. Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol
21. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial
22. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
23. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
24. Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia
25. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results
26. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting
27. Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation
28. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study
29. A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT).
30. Community Health Status and Its Association with Patient Outcome Post Allogeneic Hematopoietic Cell Transplantation [HS1]2500 Character Limit of Body of Abstract without Spaces or Title
31. Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation
32. IL-6 Is Not Significantly Associated with Quality of Life Symptoms in Allogeneic Hematopoietic Cell Transplant Recipients Following Tocilizumab
33. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
34. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors
35. Peripheral Blood Grafts for T Cell–Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome
36. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
37. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
38. 24-hour cancer clinic: An approach to same-day care.
39. Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation
40. Genomic Mechanisms of SES-Related Outcome Disparities in Hematopoietic Cell Transplantation
41. Use of Propylene Glycol-Free Melphalan Conditioning in Light Chain Amyloidosis Patients Undergoing Autologous Hematopoietic Cell Transplantation is Associated with Significantly Lower Hospitalization Days
42. Propranolol Inhibits Stress-Related Gene Expression Profiles Associated with Adverse Clinical Outcomes in Autologous Hematopoietic Cell Transplantation Recipients
43. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- versus -host disease: low incidence of lower gastrointestinal tract disease
44. The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe)
45. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome
46. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful
47. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation
48. Alpha‐1‐antitrypsin for the treatment of steroid‐refractory acute gastrointestinal graft‐versus‐host disease
49. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
50. Application of the CIBMTR Survival Outcomes Calculator to CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.